Skip to main content
. 2023 Oct 2;29(10):2570–2576. doi: 10.1038/s41591-023-02589-w

Extended Data Fig. 2. Elranatamab-induced changes in soluble BCMA.

Extended Data Fig. 2

BCMA, B-cell maturation antigen; CR, complete response; MR, minimal response; PD, progressive disease; PR, partial response; QW, once weekly; sBCMA, soluble B-cell maturation antigen; sCR, stringent complete response; SD, stable disease; VGPR, very good partial response.